更新于：2024-11-01

LCS

LCS干混悬剂

更新于：2024-11-01

概要

概要

基本信息

药物类型

化学药

别名

靶点-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

厦门恩成制药有限公司

在研机构

厦门恩成制药有限公司

非在研机构-

最高研发阶段临床申请

首次获批日期-

最高研发阶段(中国)临床申请

特殊审评-

登录后查看时间轴

关联

100 项与 LCS干混悬剂相关的临床结果

登录后查看更多信息

100 项与 LCS干混悬剂相关的转化医学

登录后查看更多信息

100 项与 LCS干混悬剂相关的专利（医药）

登录后查看更多信息

项与 LCS干混悬剂相关的文献（医药）

2013-03-01·The Journal of Nutritional Biochemistry2区 · 医学

Lactobacillus casei Shirota protects from fructose-induced liver steatosis: A mouse model

2区 · 医学

Article

作者: Astrid Spruss ; Ina Bergheim ; Carolin Stahl ; Markus Schröder ; Walter Vetter ; Sabine Wagnerberger ; Stephan C. Bischoff ; Giridhar Kanuri

To test the hypothesis that Lactobacillus casei Shirota (Lcs) protects against the onset of non-alcoholic fatty liver disease (NAFLD) in a mouse model of fructose-induced steatosis, C57BL/6J mice were either fed tap water or 30% fructose solution +/- Lcs for 8 weeks. Chronic consumption of 30% fructose solution led to a significant increase in hepatic steatosis as well as plasma alanine-aminotransferase (ALT) levels, which was attenuated by treatment with Lcs. Protein levels of the tight junction protein occludin were found to be markedly lower in both fructose treated groups in the duodenum, whereas microbiota composition in this part of the intestine was not affected. Lcs treatment markedly attenuated the activation of the Toll-like receptor (TLR) 4 signalling cascade found in the livers of mice only treated with fructose. Moreover, in livers of fructose fed mice treated with Lcs peroxisome proliferator-activated receptor (PPAR)-γ activity was markedly higher than in mice only fed fructose. Taken together, the results of the present study suggest that the dietary intake of Lcs protects against the onset of fructose-induced NAFLD through mechanisms involving an attenuation of the TLR-4-signalling cascade in the liver.

Nutrients2区 · 医学

Effects of Fermented Milk Containing Lacticaseibacillus paracasei Strain Shirota on Constipation in Patients with Depression: A Randomized, Double-Blind, Placebo-Controlled Trial

2区 · 医学

ArticleOA

作者: Zhang, Ming ; Liu, Ning ; Li, Yixuan ; Zhang, Xiaomei ; Zhang, Qi ; Ren, Yimei ; Wang, Ran ; Ren, Fazheng ; Chen, Shanbin ; Zhang, Yan

Probiotics have been shown to benefit patients with constipation and depression, but whether they specifically alleviate constipation in patients with depression remains unclear. The aim of this study was to investigate the effect of Lacticaseibacillus paracasei strain Shirota (LcS), formerly Lactobacillus casei strain Shirota, on constipation in patients with depression with specific etiology and gut microbiota and on depressive regimens. Eighty-two patients with constipation were recruited. The subjects consumed 100 mL of a LcS beverage (108 CFU/mL) or placebo every day for 9 weeks. After ingesting beverages for this period, we observed no significant differences in the total patient constipation-symptom (PAC-SYM) scores in the LcS group when compared with the placebo group. However, symptoms/scores in item 7 (rectal tearing or bleeding after a bowel movement) and items 8–12 (stool symptom subscale) were more alleviated in the LcS group than in the placebo group. The Beck Depression Index (BDI) and Hamilton Depression Rating Scale (HAMD) scores were all significantly decreased, and the degree of depression was significantly improved in both the placebo and LcS groups (p < 0.05), but there was no significant difference between the groups. The LcS intervention increased the beneficial Adlercreutzia, Megasphaera and Veillonella levels and decreased the bacterial levels related to mental illness, such as Rikenellaceae_RC9_gut_group, Sutterella and Oscillibacter. Additionally, the interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) levels were significantly decreased in both the placebo and LcS groups (p < 0.05). In particular, the IL-6 levels were significantly lower in the LcS group than the placebo group after the ingestion period (p < 0.05). In conclusion, the daily consumption of LcS for 9 weeks appeared to relieve constipation and improve the potentially depressive symptoms in patients with depression and significantly decrease the IL-6 levels. In addition, the LcS supplementation also appeared to regulate the intestinal microbiota related to mental illness.

100 项与 LCS干混悬剂相关的药物交易

登录后查看更多信息